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doi:10.1016/j.jfma.2011.11.007Background/Purpose: Despite availability of effective antihypertensives, blood pressure (BP)
control is usually inadequate. The Reasons for not Intensifying Antihypertensive Treatment
(RIAT) registry evaluated the reasons behind not modifying treatment in an international,
cross-sectional study in 16 countries.
Methods and results: The Taiwanese cohort of RIAT consisted of 8922 patients with untreated/
uncontrolled essential hypertension recruited from 22 centers in the country. At the first visit,
physicians selected target BP and antihypertensive treatment, and at the next three visits they
measured BP and modified treatment/provided justification for not modifying treatment. Mean
target BP selected by physicians was 134.6/84.6  5.1/5.0 mmHg, respectively. Patients’ indi-
vidual risk stratification determined the BP goals. More patients achieved targets according to
the physicians’ opinion than based on actual BP measurements: visit 2e50.6% vs. 48.6%; visit
3e58.4% vs. 55.2%; and visit 4e61.2% vs. 57.0%. At each visit, treatment remained unchanged
for >60% patients not reaching target; the most common reason for this at visit 2 was theCardiology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang
Kaohsiung, Taiwan.
h.org.tw (C.-J. Wu).
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Therapeutic inertia in antihypertensive treatment 769assumption that the time was too short to assess new drug therapy and at visits 3 and 4 was the
assumption that target was reached/had almost been reached.
Conclusion: About 40% Taiwanese hypertensive patients in RIAT did not reach BP targets after
an average of 4 months’ follow-up. The most common reason for not modifying treatment was
the assumption that the target had been reached or had almost been reached.
Copyright ª 2011, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Hypertension is the most common and important cardiovas-
cular disease (CVD). It is defined as systolic blood pressure
(SBP) 140 mmHg and/or diastolic blood pressure (DBP)
90 mmHg and/or receiving antihypertensive medication.1
In the past few years, Taiwan has witnessed a rapid trans-
formation in the economy, which has led to changes in die-
tary patterns and lifestyles. These changes also have greatly
influenced the prevalence of CVD, which is strongly deter-
mined by hypertension.2 It has been observed that about
one-third of deaths in Taiwan are caused by hypertension-
related conditions in conjunction with comorbidities.3
According to a report by the World Health Organization
(WHO), hypertension contributes significantly (4.5%) to the
global disease burden.4 It is estimated that hypertension
causes 7.1 million premature deaths worldwide.4e6 There
have been many international guidelines suggesting target
BP values for the management of arterial hypertension,
according to the presence of risk factors or concomitant
CVDs, such as maintaining BP at 130/80 mmHg or lower in
diabetic and kidney disease.6,7
With the objective of supporting physicians in their
active management of hypertensive patients, a worldwide
survey on the assessment of the Reasons for not Intensifying
Antihypertensive Treatment (RIAT) trial was conducted.8
The previous RIAT survey identified three main reasons
for not intensifying antihypertensive therapy: (i) The
assumption that the time after initiating new therapy was
too short to evaluate the efficacy of the treatment; (ii)
either a visible improvement or an approximate achieve-
ment of target BP was observed; and (iii) the physicians
were satisfied with adequate self-measured BP readings.9
A regional study had reported that the prescription
patterns for uncomplicated hypertension in Taiwan were
inconsistent with international clinical guidelines.4 Based
on the reason of considerable differences in the health
insurance system in Taiwan, and the lack of a real-world
practice report regarding antihypertensive treatment
from Taiwan, the RAIT study was then initiated. The
present paper describes the results of this study in Taiwan,
and explores our physicians’ practice in teaching/commu-
nity hospitals, comparing this with global practice (by
primary physicians) in treating hypertensive patients.
Materials and methods
Study design
Thedetails of study design, sampling ofmedical practitioners,
instruments, and measures and diagnostic conventions usedin RIAT have been published previously.8,10 The RIAT program
was an international, cross-sectional study of unselected
patients attending primary care settings. These patients were
recruited by a representative sample of medical practi-
tioners. RIAT was carried out in three stages:
1. Identification of the reference guidelines for manage-
ment and therapeutic targets for hypertensive patients.
2. Data collection to evaluate the variance between
individual patient targets defined by medical practi-
tioners and national/international guidelines.
3. A prospective registry to collect patient data at base-
line and determine individual target BP values. Subse-
quent follow-up visits assessed whether or not BP
targets were achieved during patient monitoring. It also
included comprehensive data collection on other
cardiovascular risk factors, target organ damage and
associated clinical conditions related to hypertension.
The number of visits and the registry follow-up duration
was decided by the investigator according to local clinical
practice and was applicable to all physicians practicing in
22 community hospitals or medical centers in Taiwan. The
study included four follow-up visits. The mean duration
between each visit was approximately 1 month, 2 months
and 3 months, respectively (see Fig. 1).
The program followed a natural approach to hyperten-
sion management, and physicians followed their usual
medical practice. The physician could select an appropriate
antihypertensive drug regimen at each visit.Patients
Adult hypertensive patients (male/female) with essential
hypertension that was either ‘newly diagnosed and
untreated’ or ‘previously treated and uncontrolled’ were
recruited. Patients with known secondary curable hyper-
tension (i.e., pheochromocytoma, aldosterone-producing
adenoma and Cushing’s disease) were excluded. However,
patients with renal disease were not excluded. Written
informed consent was obtained from all patients.
BP targets and BP changes during the study were
described and compared according to the grade of hyper-
tension. The grades were defined according to the Joint
National Committee (JNC) VII recommendations2 or 2003
WHO Guidelines for hypertension management11 as follows:
- grade I: SBP 140e159 mmHg or DBP 90e99 mmHg;
- grade II: SBP 160e179 mmHg or DBP 100e109 mmHg;
and
- grade III: SBP 180 mmHg or DBP 110 mmHg.
Table 1 Baseline demographic characteristics.
Number of patients
Gender: male, n (%)
Age (years), mean  SD
Body mass index (kg/m2), mean  SD
SBP (mmHg), mean  SD
DBP (mmHg), mean  SD




Family history of premature cardiovascular disease (%)
Smoker (%)
Body mass index 30 kg/m2 (%)
Other risk factors (%)
Associated or previous clinical conditions, n (%)
Cerebrovascular disease (%)
Coronary heart disease (%)
Retinopathy (%)
Peripheral arterial disease (%)
Congestive heart failure (%)






Abbreviations: CV, cardiovascular; DBP, diastolic blood pressure; SBP,
test for categorical variables.
Visit V1
Inclusion =  Baseline
N = 8,922 patients
Visit V2
Follow-up visit
N = 8,521 patients
Visit V3
Follow-up visit
N = 7,935 patients
Visit V4
Follow-up visit
N = 7,444 patients
32.1 ± 14.3 days
56.7 ± 14.3 days
82.2 ± 20.3 days
Figure 1 Study schedule.
770 C.-J. Wu et al.Statistical analysis
Statistical analysis was based on all patients enrolled in the
registry. Since this was a registry study, no sample size
calculation was applied to it. Data were summarized using
mean, median, standard deviation (SD) and range for
continuous parameters; and counts and percentages for
categorical parameters. Relative and absolute differences
between the target value and the value at the visit were
calculated. All tests performed were bilateral with a risk
a equal to 5%. Analysis was performed with the SAS soft-
ware, v8.2 (SAS Institute, Cary, North Carolina, USA).
Results
From January 2004 to November 2005, a total of 8,922
(4488 men) patients were recruited in 22 centers in Taiwan.
Of these, 7444 (83.4%) patients completed the study. The
last follow-up visit was performed in July 2006. The base-
line characteristics of this population are presented in
Table 1. At baseline, average SBP was 154.3  17.0 mmHg
and average DBP was 86.8  11.8 mmHg. The most
frequently observed risk factor in this population was dia-
betes (nZ3867; 43.4%), followed by dyslipidemia (nZ3199;
36.0%) and sedentary lifestyle (nZ2841; 32.0%). Hyper-
tension was newly diagnosed in 1270 (14.3%) patients. AtTaiwan data Global data p
8922 35,302
4488 (50.3) 17,722 (50.2)
62.7  12.0 59.2  12.6 <0.01
26.1  3.9 25.4  3.7 <0.01
154.3  17.0 158.7  15.3 <0.0001
86.8  11.8 95.2  12.0 <0.0001
3867 (43.4) 9954 (28.2) <0.0001
3199 (36.0) 9231 (26.2) <0.0001
2841 (32.0) 10637 (30.2) <0.005
1638 (18.4) 7068 (20.1) <0.001
1441 (16.2) 9328 (26.4) <0.0001
1280 (14.5) 5175 (14.7) NS
187 (2.2) 834 (2.5) NS
1637 (18.4) 3639 (10.3) <0.0001
1371 (15.4) 3706 (10.5) <0.0001
780 (8.8) 1756 (5.0) <0.0001
437 (4.9) 1320 (3.8) <0.0001
384 (4.3) 2009 (5.7) <0.0001
7096 (79.5) 22,887 (64.8) <0.0001
2825 (39.8) 13824 (60.4) <0.0001
2685 (37.8) 5768 (25.2) <0.0001
1219 (17.2) 2403 (10.5) <0.0001
367 (5.2) 692 (3.0) <0.0001
systolic blood pressure; SD, standard deviation. p by chi-squared
Therapeutic inertia in antihypertensive treatment 771the time of inclusion, 4462 (55.7%), 2613 (32.6%) and 941
(11.7%) patients had grade I, II and III hypertension,
respectively. The prevalence of risk factors or associated
clinical conditions was generally higher in the Taiwanese
cohort than in the global RIAT cohort, with the exception of
smoking and family history of CVD (see Table 1). Baseline
BP was lower in the Taiwanese cohort than in the global
RIAT cohort, however, probably reflecting the higher
proportion of patients already on treatment (proportion in
Taiwan 79.5% vs. global 64.8%).
The assessment of target organ damage revealed that
711 (8.0%) patients had microalbuminuria, 926 (10.4%)
patients had macroalbuminuria, 936 (10.5%) patients had
increased serum creatinine and 1036 (11.7%) patients had
left ventricular hypertrophy.
At the time of inclusion, 7096 (79.5%) patients were
receiving at least one antihypertensive agent. Of these, 2825
(39.8%) received monotherapy, 2685 (37.8%) received two
treatments, 1219 (17.2%) received three treatments and 367
(5.2%) patients received more than three treatments,
see Table 1. The frequency of prescribed antihypertensive
classes (alone or in combination) was: angiotensin convert-
ing enzyme (ACE) inhibitors, 14.7%; angiotensin receptor
blockers, 63.0%; calcium-channel blockers, 46.0%; diuretics,
28.1%; beta-blockers, 32.8%; and others, 10.3%.
Primary endpoints
Defining the target
According to international guidelines, the mean target SBP
was 134.6  5.1 mmHg, whereas the mean target DBP was
84.6  5.0 mmHg. The BP goals set by physicians at baseline
were significantly lower for patients with diabetes mellitus
(SBP Z 130.6  2.9 mmHg and DBP Z 80.7  2.6 mmHg)
and were stricter than the average goal for patients with
diabetes in the global RIAT cohort (SBP Z 130.0 
5.7 mmHg and DBP Z 82.5  4.8 mmHg).10 BP goals for
patients with dyslipidemia were significantly lower (SBP Z




Mean  SD 137.3  4.7
Dyslipidemia n 4216
Mean  SD 134.6  5.2
Physical inactivity n 5850
Mean  SD 134.4  5.2
Family history of premature CVD n 5453
Mean  SD 134.4  5.2
Smoker n 7288
Mean  SD 134.3  5.2
Body mass index 30 kg/m2 n 7409
Mean  SD 134.3  5.2
Other risk factors n 4616
Mean  SD 134.0  5.1
Abbreviations: CVD, cardiovascular disease; DBP, diastolic blood prespatients without dyslipidemia, see Table 2. A significant
difference was observed in the individual target SBP and
DBP values based on the number of associated risk factors.
With no risk factors, the target values were 137.3 
4.5 mmHg for SBP and 87.3  4.4 mmHg for DBP; for one to
two risk factors, the target values were 134.4  5.2 mmHg
for SBP and 84.4  5.0 mmHg for DBP; and for three or more
factors, the target values were 132.2  4.6 mmHg for SBP
and 82.3  4.2 mmHg for DBP.
Identifying the reasons for not intensifying
antihypertensive treatment
At visit 2, 29.4% of Taiwanese patients did not reach their
BP goal, but had no change in antihypertensive treatment
compared to 50.2% of patients in the global RIAT cohort for
the same period, see Table 3. At visit 2, the two most
frequent reasons for not modifying treatment were the
time factor (51.8% of cases) and the assumption that the
target was almost reached or had been achieved (17.8% of
cases). At visit 4, 23.1% of the Taiwan patients still had not
reached their BP goal and did not have their treatment
changed, compared to 9.8% of patients in the global RIAT
cohort for the same period, see Table 3. At Visit 4, the most
commonly cited reason for not modifying treatment was
the assumption that the target was almost reached or had
been achieved (29.4%) and the time factor, i.e. the
assumption that the time was too short for assessing
optimum efficacy of the therapy (18.6%), see Table 3.
Secondary endpoints
Achieving the target
At baseline, the average SBP was 154.3  17.0 mmHg and
the average DBP was 86.8  11.8 mmHg. At the last visit,
these values averaged 135.2  14.7 mmHg and
78.7  9.6 mmHg, respectively (p <0.0001 vs. baseline).
The JNC VII target values were more likely to be achieved in
overall patients than in patients with diabetes (63.6% vs.
26.8%, p <0.005). Table 4 summarizes the number andin Taiwanese patients.
SBP p value Target DBP p value
Yes No Yes
3867 4734 3867
130.6  2.9 <0.001 87.3  4.4 80.7  2.6 <0.001
3199 4216 3199
133.4  5.0 <0.001 84.7  5.0 83.5  4.7 <0.001
2840 5850 2840
134.3  5.2 0.131 84.4  5.0 84.3  5.0 0.210
1638 5453 1638
134.9  5.5 0.005 84.5  5.0 84.9  5.0 0.002
1441 7288 1441
134.8  5.3 0.002 84.3  5.0 84.8  5.0 0.002
1280 7409 1280
134.4  5.1 0.526 84.4  5.0 84.5  5.0 0.565
187 4616 187
136.6  5.0 <0.001 84.0  4.9 86.6  4.8 <0.001
sure; SBP, systolic blood pressure; SD, standard deviation.
Table 3 Reasons for not modifying blood pressure treatment if the targets had not been reached.



















Time (Short timelines) 1318 (51.8) 14309 (85.3) 474 (24.0) 9870 (76.4) 320 (18.6) 1098 (34.7)
Target almost reached/achieved 452 (17.8) 526 (3.1) 632 (32.0) 1056 (8.2) 505 (29.4) 627 (19.8)
Drug discontinuation and
poor compliance
118 (4.6) 327 (2) 120 (6.1) 277 (2.7) 83 (4.8) 198 (6.3)
Exceptional circumstances 377 (14.8) 416 (2.5) 448 (22.6) 474 (3.7) 482 (28.0) 506 (16.0)
Reduction of other risk factors 55 (2.2) 361 (2.2) 50 (2.5) 232 (1.8) 29 (1.7) 125 (3.9)
Side effects 55 (2.2) 107 (0.6) 49 (2.5) 87 (0.7) 55 (3.2) 75 (2.4)
Other reasons 171 (6.7) 723 (4.3) 205 (10.3) 919 (7.1) 245 (14.2) 537 (16.9)
772 C.-J. Wu et al.percentage of patients not having reached the target BP at
follow-up visits according to measured BP values or the
physician’s opinion; this percentage decreased over the
course of the program. Fig. 2 displays the percentage of
patients achieving target BP values and the modification of
treatment at each follow-up visit.
Changing antihypertensive treatment when target
BP is reached
When target BP values were reached according to the
physician, a change in therapy was rarely undertaken (3.6%
and 4.5% at visits 2 and 4, respectively; see Fig. 2). The
most commonly cited reason was the side-effects of
prescribed medication in one-quarter to one-third of cases.Discussion
Hypertension is often poorly controlled despite increased
awareness of its deleterious consequences, the availability
of effective and well-tolerated antihypertensive drugs, and
various international guidelines for its management. The
WHO guidelines for hypertension management recommend
targeting individual BP goals according to risk stratifica-
tion.11 Interestingly, a Swiss survey revealed that practi-
tioners based the target BP values for hypertensive patients
on their baseline BP values rather than on individual risk
stratification.9 Therapeutic inertia, however, is another
major obstacle in BP treatment that is mostly due to lack of
understanding of the comparative risk-benefit profile of BPTable 4 Number (and percentage) of patients not reaching targ
blood pressure values and change of treatment.





According to the physicians’
opinion
4190 (49.4) 21162 (63.0)
According to reported blood
pressure values
4356 (51.4) 21811 (65.0)
Treatment not changed 2572 (61.4) 16904 (79.9)
Treatment changed 1615 (38.6) 4247 (20.1)management, and to resistance to implement the relevant
guidelines.12,13
According to the Nutrition and Health Survey in Taiwan
(NAHSIT) conducted during 1993e1996, only 2% of hyper-
tensive males and 5% of hypertensive females had their
hypertension under control.3 The second nationwide survey
in 2002, the Taiwanese Survey on Hypertension, Hypergly-
cemia and Hyperlipidemia (TwSHHH) found that awareness,
treatment and control of hypertension was significantly
improved in the period between NAHSIT and TwSHHH.14
Although the focus of the present study is on Taiwan, we
have compared the results with those of the global RIAT
study in order to understand the similarities and critical
differences. The percentage of newly diagnosed hyper-
tensive patients was low, while the majority of the patients
were already receiving treatment. The percentage of
patients with risk factors (diabetes, dyslipidemia and
physical inactivity) was significantly higher in the Taiwa-
nese cohort than in the global cohort, but the percentage
of patients with risk factors (family history of premature
CVD and smoking) was significantly lower. This might reflect
a selection bias among Taiwanese practitioners. The
percentage of patients receiving at least one treatment
at visit 1 was higher in Taiwanese patients (79.5%) when
compared with global data (64.8%). However, SBP
(158.7  15.3 mmHg) and DBP (95.2  12.0 mmHg) values
for global patients were higher than those for Taiwanese
patients.
The treatment was not modified in 29.9%, 24.9% and
23.1% of Taiwanese patients at visits 2, 3 and 4,et blood pressure according to physicians’ opinion or reported









3294 (41.6) 15880 (47.0) 2881 (38.8) 5152 (16.0)
3547 (44.8) 16723 (50.0) 3194 (43.0) 6200 (19.0)
2009 (61.0) 13034 (82.1) 1744 (60.6) 3240 (62.9)
1283 (39.0) 2838 (17.9) 1135 (39.4) 1910 (37.1)
Figure 2 Percentage of patients achieving the target BP
values and modification of treatment.
Therapeutic inertia in antihypertensive treatment 773respectively, despite not having reached the target BP
values. These results differ from the global results. The
most commonly cited reason at all visits for global patients
not reaching their BP targets and not having treatment
modification was physicians’ assumption that the time was
too short to assess the efficacy of treatment. In Taiwanese
patients, however, although the time factor was the most
commonly cited reason at visit 1, the most common reason
at the last two visits was the physicians’ assumption that the
target BP values were reached or had almost been reached.
At the end of this study, about 61% of Taiwanese patients
achieved BP targets in physicians’ opinions and 57% ach-
ieved their targets according to the BP values that were
measured. In the global study, however, a significantly
higher percentage of patients reached their BP targets in
physicians’ opinions (84%) and according to the BP values
measured (81%). Thus, despite the higher percentage of
patients having at least one cardiovascular risk in the
Taiwanese cohort, therapeutic inertia was higher among
Taiwanese practitioners than in the global data, resulting in
a higher number of patients not treated to target at visit 4
in Taiwan. This is noteworthy because at baseline the
Taiwanese practitioners defined stricter BP targets than
those reported in the global analysis for certain subgroups
of hypertensive patients (e.g. those with diabetes), and
had less therapeutic inertia at visit 2 (target not reached/
no change in treatment: Taiwanese practitioners 52% vs.
global practitoiners 85%). According to global data, the
percentage of patients achieving BP targets was higher in
previously untreated patients (92%) than in treated patients
(80%). When the target value was reached for the first time,
30.7% of patients were taking a single drug, 36.8% were
receiving two drugs and 22.3% were receiving three treat-
ments. A more accurate treatment adaptation taking into
consideration hypertension management guidelines and
other risk factors (e.g. diabetes, dyslipidemia and physical
inactivity) could provide better results.
Over and above achieving BP targets, proper treatment
modification for keeping the BP values below their targets
is crucial. Earlier studies have identified core actions forpractitioners to instigate in order to achieve above-
mentioned objectives15 and have discussed a number of
innovative approaches, such as decision support systems,
patient-centered counseling or revisiting patient profiles.2
There is also the need for additional clinical trials to vali-
date different therapeutic goals for high-risk patients
instead of the current agreed SBP goal of 130 mmHg.16
There are some limitations to our study. As this was not
a population-based survey, the findings do not represent
the general population. Secondly, four visits within 4
months to specifically manage hypertension may not be
realistic in practice. Additionally, no pre-specified
approach was recommended to intensify antihypertensive
treatment. Thus, the results, particularly those related to
the high BP control rate, may be difficult to reconcile at
a larger scale. The participating physicians were practicing
in community hospitals or large medical centers so the
results may not reflect real-world practice for primary care
physicians in Taiwan.
Conclusion
Individual target BP values were aligned with international
guidelines in the majority of Taiwanese hypertensive
patients, a high percentage of whom were receiving anti-
hypertensive treatment. Nonetheless, achievement of the
target BP value was better in global patients than in
Taiwanese patients, probably on account of the higher
therapeutic inertia among Taiwanese practitioners at visit
4. The most commonly cited reason for not modifying
treatment despite not achieving target BP values was the
assumption that the patients had reached or almost ach-
ieved target BP.
Hypertension control in Taiwan may improve if aware-
ness and adherence to BP management guidelines is
increased among Taiwanese practitioners, and steps should
be taken to counter therapeutic inertia in the long-term
management of hypertension.
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